Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 3/20 | 0.35 |
| ▸ | METAP1 | P53582 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12920124 | 0.74 | REN (0.44) | RENMETAP2METAP1 | |
| SCHEMBL3607116 | 0.74 | METAP2 (0.32) | RENMETAP2 | |
| SCHEMBL1866570 | 0.73 | EPHX1 (0.34) | — | |
| SCHEMBL7739454 | 0.72 | SPHK1 (0.39) | — | |
| SCHEMBL7737873 | 0.72 | SPHK1 (0.39) | — | |
| SCHEMBL7738681 | 0.72 | SPHK1 (0.39) | — | |
| SCHEMBL7738043 | 0.72 | SPHK1 (0.39) | — | |
| SCHEMBL7741163 | 0.72 | SPHK1 (0.39) | — | |
| SCHEMBL970253 | 0.70 | REN (0.40) | RENMETAP2METAP1 | |
| SCHEMBL7732866 | 0.70 | SPHK1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | REN 298/4885METAP2 44/4885METAP1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.